NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Shareholder Letter, Including Corporate Update
D
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic noted that 2022 was a “transformative” year for HeartBeam, highlighted by ongoing advancements in the company’s product launch timeline for the HeartBeam AIMIGo(TM) 12-Lead 3D Vector Electrocardiogram (“ECG”) device and HeartBeam AIMI(TM). Vajdic stated that he could not be more enthusiastic about the future of the company or its ability to scale the commercialization path. He also pointed out that the company’s mission to deliver medical-grade heart-attack detection that is with the patient anytime, anywhere could not be timelier. “Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the shareholder letter. “By providing remote, 12-lead 3D vector ECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting. We expect the HeartBeam AIMI system for use in acute care settings to receive regulatory approval in the near future. We are in discussions with the FDA and plan to meet with them soon and expect HeartBeam AIMI to be cleared in the Q1 2023 time frame.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
D
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Vajdic noted that 2022 was a “transformative” year for HeartBeam, highlighted by ongoing advancements in the company’s product launch timeline for the HeartBeam AIMIGo(TM) 12-Lead 3D Vector Electrocardiogram (“ECG”) device and HeartBeam AIMI(TM). Vajdic stated that he could not be more enthusiastic about the future of the company or its ability to scale the commercialization path. He also pointed out that the company’s mission to deliver medical-grade heart-attack detection that is with the patient anytime, anywhere could not be timelier. “Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the shareholder letter. “By providing remote, 12-lead 3D vector ECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting. We expect the HeartBeam AIMI system for use in acute care settings to receive regulatory approval in the near future. We are in discussions with the FDA and plan to meet with them soon and expect HeartBeam AIMI to be cleared in the Q1 2023 time frame.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
